Valuation
- Market cap
- 156,613,000
- Revenue TTM
- $0
- Net income TTM
- $-293,420,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 57,000
- Avg volume
- 190,584
- Day's range
- $3.22 – $3.37
- Shares out
- 47,748,000
- Stochastic %K
- 16%
- Beta
- -0.10
- Analysts
- Sell
- Price target
- $10.33
Company profile
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in...
Show more
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 600 7373
- Website
- https://www.minervaneurosciences.com
- Address
- 1500 District Avenue, Burlington, United States
Latest news
No headlines yet.
